SELLAS Life Sciences Group (SLS) Earnings Date & Reports
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications... Show more
SLS is expected to report earnings to rise 14.29% to -7 cents per share on August 07
Q2'25
Est.
$-0.08
Q1'25
Beat
by $0.04
Q4'24
Beat
by $0.04
Q3'24
Beat
by $0.03
Q2'24
Beat
by $0.04
The last earnings report on May 13 showed earnings per share of -7 cents, beating the estimate of -10 cents. With 15.90M shares outstanding, the current market capitalization sits at 194.57M.